Novartis Pharmaceuticals Corp v. Secretary United States Department of Health, decided by Third Circuit on September 11, 2025, resulted in a defendant win outcome. The Third Circuit affirmed the Distr...
Vanda Pharmaceuticals, Inc. v. FDA, decided by D.C. Circuit on August 15, 2025, resulted in a mixed outcome. The D.C. Circuit reviewed the FDA's refusal to approve Vanda Pharmaceuticals' supplemental ...
Actavis Laboratories Fl, Inc. v. United States, decided by Federal Circuit on March 21, 2025, resulted in a defendant win outcome. The case concerns the interpretation of the "substantially all" limit...